Gardiquimod

SKU: orb1308280

Description

Gardiquimod is a selective TLR7 agonist and imidazoquinoline analog that suppresses HIV-1 infection in macrophages and activated PBMCs at concentrations below 10 µM. This small molecule is utilized in immunology and virology research to study innate immune activation and antiviral mechanisms in both cellular and animal models.

Research Area

Immunology & Inflammation, Infectious Disease & Virology, Protein Biochemistry

Key Properties

• CAS Number: 1020412-43-4
• MW: 313.4
• Purity: 99.68%
• Formula: C₁₇H₂₃N₅O
• SMILES: CCNCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
• Target: TLR,HIV Protease

Bioactivity

• In Vivo:
  Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) in combination with Dendritic cells (DCs) enhance the anti-tumor effects of NK cells.
• In Vitro:
  Administration of 6-60 μM Gardiquimod obviously inhibits HIV-1 reverse transcriptase cDNA synthesis.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

cells, carcinoma, blood, Inhibitor, Gardiquimod, HepG2, HIV, HIV Protease, HIV-1, HIVProtease, mononuclear, Human immunodeficiency virus, PBMCs, macrophages, inhibit, liver, Toll-like Receptor (TLR), TLR7, TLR8, peripheral

Compound Identifiers

PubChem CID

44592366